Get the Stockscreener App
135.32
0.64%
-0.87
Pre-market:
134.53
-0.79
-0.58%
Illumina Inc stock is traded at $135.32, with a volume of 597.53K.
It is down -0.64% in the last 24 hours and up +7.43% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$136.19
Open:
$135.65
24h Volume:
597.53K
Relative Volume:
0.34
Market Cap:
$20.68B
Revenue:
$4.28B
Net Income/Loss:
$1.26B
P/E Ratio:
17.14
EPS:
7.8957
Net Cash Flow:
$943.00M
1W Performance:
+4.45%
1M Performance:
+7.43%
6M Performance:
+47.86%
1Y Performance:
+0.08%
1-Day Range:
$132.93
$136.53
1-Week Range:
$129.99
$138.80
52-Week Range:
$68.70
$153.06
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
135.32 | 20.81B | 4.28B | 1.26B | 943.00M | 7.8957 |
|
TMO
Thermo Fisher Scientific Inc
|
579.12 | 217.89B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
231.47 | 163.05B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
688.18 | 54.48B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
138.32 | 39.22B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
226.02 | 38.34B | 15.90B | 1.28B | 2.21B | 7.2842 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
United states DNA Forensics Market to Reach USD 5.60 Billion - openPR.com
Swedbank AB Grows Position in Illumina, Inc. $ILMN - MarketBeat
Life Science Instruments & Consumables Market to Reach USD - openPR.com
Genomics in Cancer Care Market to Reach USD 72.87 Billion by 2033 | - openPR.com
Illumina Inc. Stock Underperforms Tuesday When Compared To Competitors - 富途牛牛
Genomics Market Outlook: Market to Reach US$ 118.2 Billion - openPR.com
Illumina Inc ILU Stock Analysis and ForecastTechnical Breakout Signals & Fast Growing Capital Growth - earlytimes.in
Illumina Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Is Illumina Inc Gaining or Losing Market Support? - Sahm
Illumina, Inc. $ILMN Stock Holdings Lessened by Assenagon Asset Management S.A. - MarketBeat
Canaccord Genuity Maintains Illumina (ILMN) Hold Recommendation - Nasdaq
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina (NASDAQ:ILMN) Price Target Raised to $130.00 - MarketBeat
Illumina (ILMN) Surges 3.3%: Is This an Indication of Further Gains? - Yahoo Finance
Illumina Inc. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
Douglas Lane & Associates LLC Acquires 18,914 Shares of Illumina, Inc. $ILMN - MarketBeat
Why Illumina Inc. (ILU) stock could rally stronglySwing Trade & Stepwise Trade Signal Guides - Улправда
Illumina (ILMN): Evaluating the Stock’s Valuation After Its Strategic AI-Genomics Partnership With MyOme - Yahoo Finance
Why hedge funds are buying Illumina Inc. stockJuly 2025 Rallies & Risk Controlled Stock Alerts - Улправда
Can Illumina Inc. stock deliver consistent earnings growthJuly 2025 Sector Moves & Weekly Chart Analysis and Guides - Улправда
Is Illumina Inc. stock a smart buy before Fed meetingJuly 2025 Retail & Fast Gain Stock Trading Tips - DonanımHaber
Why Illumina Inc. (ILU) stock stays on buy listsStop Loss & AI Powered Buy and Sell Recommendations - DonanımHaber
Is Illumina Inc. stock undervalued vs historical averages2025 Year in Review & Smart Money Movement Alerts - ulpravda.ru
Will Illumina Inc. stock outperform international peersWeekly Investment Report & Expert Verified Movement Alerts - ulpravda.ru
Is Illumina Inc. stock supported by innovation pipelineWeekly Trading Summary & Real-Time Price Movement Reports - Улправда
“It can’t wait until tomorrow”: How patient advocacy drives change - Illumina
DNA/Gene Microarray Market Growth Potential Examined Through - openPR.com
Illumina, Inc. $ILMN Shares Acquired by Aaron Wealth Advisors LLC - MarketBeat
Illumina Inc (NASDAQ:ILMN) Nasdaq Futures Shape Discovery Market Now - Kalkine Media
Discipline and Rules-Based Execution in ILMN Response - news.stocktradersdaily.com
Illumina Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Illumina Target of Unusually Large Options Trading (NASDAQ:ILMN) - MarketBeat
How AstraZeneca improved their genomics processing to be 60% faster, 70% more cost-effective - Amazon Web Services (AWS)
Sicart Associates LLC Has $7.89 Million Stock Position in Illumina, Inc. $ILMN - MarketBeat
Scott Davies Sells 323 Shares of Illumina (NASDAQ:ILMN) Stock - MarketBeat
How to watch Illumina's J.P. Morgan healthcare conference webcast - Stock Titan
Meet three scientists behind Illumina’s spatial assay breakthrough - Illumina
Santa Rally Looms: These 5 Stocks Often Deliver Gifts To Investors - Benzinga
Gene Prediction Tool Industry Report 2025: Precision Genomics, - openPR.com
Barclays Maintains Illumina (ILMN) Underweight Recommendation - Nasdaq
JP Morgan Maintains Illumina (ILMN) Neutral Recommendation - Nasdaq
Illumina (NASDAQ:ILMN) Given New $130.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Twists, tangles, and transcription: Does epigenetics play a role in Alzheimer's? - Illumina
Thrivent Financial for Lutherans Purchases 684,802 Shares of Illumina, Inc. $ILMN - MarketBeat
United States DNA Sequencing Market 2031 | Growth Drivers, Key - openPR.com
Illumina, Inc. $ILMN Shares Bought by Neuberger Berman Group LLC - MarketBeat
Marex Group plc Makes New $1.24 Million Investment in Illumina, Inc. $ILMN - MarketBeat
NGS Based RNA Sequencing Market is growing at a CAGR of 19.7%, - openPR.com
Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually - PR Newswire
Illumina’s AI Genomics Partnership With MyOme Might Change The Case For Investing In Illumina (ILMN) - Sahm
Nikko Asset Management Americas Inc. Increases Stake in Illumina, Inc. $ILMN - MarketBeat
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):